<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244656</url>
  </required_header>
  <id_info>
    <org_study_id>CRSP-ONC-002</org_study_id>
    <nct_id>NCT04244656</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRISPR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRISPR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and
      efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study may enroll approximately 80 subjects in total.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A (dose escalation): Incidence of adverse events</measure>
    <time_frame>From CTX120 infusion up to 28 days post-infusion</time_frame>
    <description>Adverse events defined as dose-limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (cohort expansion): Objective response rate</measure>
    <time_frame>From CTX120 infusion up to 60 months post-infusion</time_frame>
    <description>Objective response rate per International Myeloma Working Group (IMWG) response criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of CTX120 infusion and date of disease progression or death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of CTX120 infusion until date of death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CTX120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX120</intervention_name>
    <description>CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.</description>
    <arm_group_label>CTX120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥18 years.

          2. Relapsed or refractory multiple myeloma, as defined by IMWG response criteria and
             treatment with at least 2 prior lines of therapy.

          3. Eastern Cooperative Oncology Group performance status 0 or 1.

          4. Adequate renal, liver, cardiac and pulmonary organ function

          5. Female subjects of childbearing potential and male subjects must agree to use
             acceptable method(s) of contraception from enrollment through at least 12 months after
             CTX120 infusion.

        Key Exclusion Criteria:

          1. Prior allogeneic stem cell transplant (SCT).

          2. Less than 60 days from autologous SCT at time of screening and with unresolved serious
             complications.

          3. Prior treatment with any gene therapy or genetically modified cell therapy, including
             CAR T cells or natural killer cells, or BCMA-directed therapy.

          4. Evidence of direct central nervous system (CNS) involvement by multiple myeloma.

          5. History or presence of clinically relevant CNS pathology such as a seizure disorder,
             cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune
             disease with CNS involvement.

          6. Unstable angina, clinically significant arrhythmia, or myocardial infarction within 6
             months of enrollment.

          7. Active HIV, hepatitis B virus or hepatitis C virus infection.

          8. Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma,
             adequately resected and in situ carcinoma of cervix, or a previous malignancy that was
             completely resected and has been in remission for ≥5 years.

          9. Use of systemic anti-tumor therapy or investigational agent within 14 days prior to
             enrollment.

         10. Primary immunodeficiency disorder or active autoimmune disease requiring steroids
             and/or other immunosuppressive therapy.

         11. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewelina Morawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>CRISPR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>+1 877-214-4634</phone>
    <email>MedicalAffairs@crisprtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site 4</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site 3</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site 5</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site 6</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>CRISPR-Cas9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

